IL304467A - Pharmaceutical compositions for the treatment of breast cancer and methods of using them - Google Patents

Pharmaceutical compositions for the treatment of breast cancer and methods of using them

Info

Publication number
IL304467A
IL304467A IL304467A IL30446723A IL304467A IL 304467 A IL304467 A IL 304467A IL 304467 A IL304467 A IL 304467A IL 30446723 A IL30446723 A IL 30446723A IL 304467 A IL304467 A IL 304467A
Authority
IL
Israel
Prior art keywords
methods
pharmaceutical compositions
breast cancers
treating breast
treating
Prior art date
Application number
IL304467A
Other languages
English (en)
Hebrew (he)
Original Assignee
Univ Tennessee Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/151,108 external-priority patent/US20210228529A1/en
Application filed by Univ Tennessee Res Found filed Critical Univ Tennessee Res Found
Publication of IL304467A publication Critical patent/IL304467A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IL304467A 2021-01-15 2023-07-13 Pharmaceutical compositions for the treatment of breast cancer and methods of using them IL304467A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/151,108 US20210228529A1 (en) 2012-07-13 2021-01-15 Pharmaceutical compositions for treating breast cancers and methods of uses thereof
PCT/US2022/012631 WO2022155543A1 (en) 2021-01-15 2022-01-14 Pharmaceutical compositions for treating breast cancers and methods of uses thereof

Publications (1)

Publication Number Publication Date
IL304467A true IL304467A (en) 2023-09-01

Family

ID=82448697

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304467A IL304467A (en) 2021-01-15 2023-07-13 Pharmaceutical compositions for the treatment of breast cancer and methods of using them

Country Status (10)

Country Link
EP (1) EP4277613A1 (ja)
JP (1) JP2024503718A (ja)
KR (1) KR20230163362A (ja)
CN (1) CN116981451A (ja)
AU (1) AU2022208712A1 (ja)
BR (1) BR112023014247A2 (ja)
CA (1) CA3205212A1 (ja)
IL (1) IL304467A (ja)
MX (1) MX2023008375A (ja)
WO (1) WO2022155543A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115369089A (zh) * 2022-08-11 2022-11-22 中山大学孙逸仙纪念医院 两种er阳性her-2阴性乳腺癌cdk4/6抑制剂耐药株及其构建方法和用途
CN117257994B (zh) * 2023-11-21 2024-03-01 北京大学人民医院 动物模型的构建方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2453981T3 (es) * 2005-08-31 2014-04-09 University Of Tennessee Research Foundation Tratamiento de síntomas de enfermedad renal con moduladores selectivos de receptor de andrógenos (SARM)
US10987334B2 (en) * 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
EP3474841B1 (en) * 2016-06-22 2022-03-16 Ellipses Pharma Ltd Ar+ breast cancer treatment methods

Also Published As

Publication number Publication date
KR20230163362A (ko) 2023-11-30
CA3205212A1 (en) 2022-07-21
WO2022155543A1 (en) 2022-07-21
BR112023014247A2 (pt) 2023-10-03
JP2024503718A (ja) 2024-01-26
AU2022208712A1 (en) 2023-08-10
CN116981451A (zh) 2023-10-31
EP4277613A1 (en) 2023-11-22
MX2023008375A (es) 2023-10-05

Similar Documents

Publication Publication Date Title
IL300067A (en) Preparations and methods for the treatment of cancers
IL304467A (en) Pharmaceutical compositions for the treatment of breast cancer and methods of using them
EP4034138A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIQUID CANCERS
IL268814A (en) Preparations and methods for the treatment of cancer
IL285917A (en) A pharmaceutical preparation that combines an immunological and chemotherapy method to treat cancer
EP4171606A4 (en) COMPOSITIONS AND METHODS FOR TREATING COVID-19
IL276203A (en) Compounds and methods for treating cancer
IL289251A (en) Methods and preparations for the treatment of pancreatic cancer
IL288787A (en) Methods and preparations to improve results in cancer patients
IL309662A (en) Compositions and methods for treating cancer
IL312844A (en) Methods and preparations for the treatment of cancer
IL312846A (en) Methods and preparations for the treatment of cancer
IL287538A (en) Preparations and methods for the treatment of cancer
GB202018015D0 (en) Composition and methods for the treatment of intestinal cancer
IL308766A (en) Compositions and methods for treating prostate cancer
EP4149508A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF CANCER
EP4114864A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP4111202A4 (en) METHODS OF TREATING CANCER
GB202215066D0 (en) Bifidobacterium and compositions thereof for breast cancer treatment
IL304591A (en) Preparations and methods for the treatment of skin cancers
IL299039A (en) Methods and preparations for the treatment of triple-negative breast cancer
IL311698A (en) Cancer treatment methods and preparations and medicines for this
EP4237094A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE FOR THE TREATMENT OF CANCER
IL308642A (en) Diagnostic methods and compositions for the treatment of cancer
IL312037A (en) Endoxifen for the treatment of cancer